Diabetologia (2017) 60:1801–1812 DOI 10.1007/s00125-017-4330-3 ARTICLE The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype 1 1,2,3 1 1 Ángela Vinué & Jorge Navarro & Andrea Herrero-Cervera & Marta García-Cubas & 1 1,4,5 1,4,5 Irene Andrés-Blasco & Sergio Martínez-Hervás & José T. Real & 1,4,5 1,5 Juan F. Ascaso & Herminia González-Navarro Received: 25 January 2017 /Accepted: 10 May 2017 /Published online: 12 June 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract blood pressure but this was independent of body weight loss. Aims/hypothesis Recent clinical studies indicate that Both drugs significantly decreasedatheromaplaquesize. glucagon-like peptide-1 (GLP-1) analogues prevent acute car- Compared with vehicle-treated control mice, lixisenatide diovascular events in type 2 diabetes mellitus but their mech- treatment generated more stable atheromas, with fewer in- anisms remain unknown. In the present study, the impact of flammatory infiltrates, reduced necrotic cores and thicker fi- GLP-1 analogues and their potential underlying molecular brous caps. Lixisenatide-treated mice also displayed dimin- high mechanisms in insulin resistance and atherosclerosis are ished IL-6 levels, proinflammatory Ly6C monocytes and investigated. activated T cells. In vitro analysis showed that, in macro- −/− +/− Methods Atherosclerosis development was evaluated in phages from Apoe Irs2 mice, lixisenatide reduced the
Diabetologia – Springer Journals
Published: Jun 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera